CD19CART

PreclinicalBiologic

IInnovative Cellular Therapeutics Co., Ltd.

CD19CART is one of 34 biologic programs targeting Hematologic Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic MalignanciesUnknown status

Hematologic MalignanciesPreclinical

Unknown status

Competition

Competitive Landscape

46 competitors in Hematologic Malignancies

#DrugCompanyPhaseTrials

Avycaz

PPhiladelphia Eye Associates

Approved

1 2

Cellcept

Roche

Phase 2

22 3

Fludara

Sanofi

Phase 2

21 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

28 5

Cytosar

Teva

Phase 2

10 6

Atgam

Novartis

Phase 2

8 7

Trexall

Jazz Pharmaceuticals

Phase 2

7 8

Prograf

VVeloxis Pharmaceuticals

Phase 2

19 9

Adriamycin

Pfizer

Phase 2

2 10

Jakafi

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Unknown status·IInnovative Cellular Therapeutics Co., Ltd.·N/A·NCT02813837·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD19CART. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19CART compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19CART. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innovative Cellular Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IInnovative Cellular Therapeutics Co., Ltd.

CD19CART

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematologic Malignancies1 trial

References

Drug Info

Quick Facts

Related News